Wire Stories
Reata Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Bardoxolone Methyl in Chronic Kidney Disease Caused by Alport Syndrome
PLANO, Texas & ZUG, Switzerland–(BUSINESS WIRE)–$RETA—Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (�Reata,� the �Company,� �our,� �us,� or �we�), a clinical-stage biopharmaceutical company, today...